Promatix Biosciences Presents Positive Preclinical Data with First-in-Class PBS293 EGFR×EphA2 Cis-Bispecific ADC Demonstrating Enhanced Tumour Selectivity

Promatix Biosciences Ltd (Promatix), an emerging UK-based biotechnology company developing innovative new classes of cancer therapies using cis-bispecific antibodies, today presented positive ...

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that the first ...

Radiance Biopharma Showcases First‑in‑Class c‑MET/EGFR Bispecific Nano ADC at Leading Global ADC Conference

Introduction of a Differentiated Bispecific Nano ADC Positioned to Compete in Major Global Oncology Markets BOSTON, MA, ...
Drug Target Review

Bispecific EGFR/EphA2-targeting ADC shows promise in colorectal cancer

PBS293-MMAE targets EGFR and EphA2, two proteins shown to be co-expressed in colorectal cancer cells. While EGFR is a clinically validated target in colorectal cancer, therapeutic antibodies such as ...
Morningstar

OncoPrecision Announces Oral Presentation of ONC001, a First-in-Class CD64-Targeting ADC for Monocytic Leukemia, at the 67th ASH Annual Meeting

NEW YORK, Dec. 1, 2025 /PRNewswire/ -- OncoPrecision Corporation ("OncoPrecision"), a translational therapeutics company developing novel antibody-based cancer therapies informed by large-scale ...
Nasdaq

ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors

SOUTH SAN FRANCISCO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the"Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline ...
MedCity News

Cancer Biotech ArriVent Lands an ADC for GI Malignancies and Makes Best-in-Class Claim

ArriVent Biopharma, a company that secures rights to drugs from emerging markets to develop them for Western markets, is adding to its pipeline with a Phase 1-ready drug candidate from China that has ...
BioWorld

First-in-class ADC Foreseen in $1B-plus Ipsen deal

The lively antibody-drug conjugate (ADC) space chalked another collaboration as Taipei, Taiwan-based Foreseen Biotechnology Co. Ltd. scored a global licensing agreement worth as much as $1.03 billion ...
MarketWatch

ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA(R) in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen ...

The MarketWatch News Department was not involved in the creation of this content. ZYNLONTA(R) in combination with glofitamab (COLUMVI(R)) demonstrated an 89.8% ORR and 77.6% CR across the 49 ...